Stuart A, Virta M, Williams K, Seppa I, et al. Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV Seropositive Children 12-24 Months. J Infect Dis 2022 Oct 19. pii: 6763323. doi: 10.1093.
PMID: 36259542